
Mevastatin
CAS No. 73573-88-3
Mevastatin ( Compactin | CS 500 | L-637,312 | ML 236B | NSC 281245 | Statin I )
产品货号. M15815 CAS No. 73573-88-3
美伐他汀或美伐他汀是从青霉中分离出来的降胆固醇剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥413 | 有现货 |
![]() ![]() |
100MG | ¥624 | 有现货 |
![]() ![]() |
500MG | ¥1806 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Mevastatin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述美伐他汀或美伐他汀是从青霉中分离出来的降胆固醇剂。
-
产品描述Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate. The compound was proposed to bind to the reductase enzyme and was named compactin. Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. Mevastatin is a pro-drug that is activated by in vivo hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.
-
体外实验Cell Viability Assay Cell Line:Caco-2 cells Concentration:0 μM, 8 μM, 16 μM, 32 μM, 64 μM, 128 μM Incubation Time:5 days Result:Caused a dose-dependent decrease in cell number.Cell Cycle Analysis Cell Line:Caco-2 cells Concentration:32 μM, 64 μM, 128 μM Incubation Time:24 hours, 48 hours, 72 hours Result:Caused a dose-dependent increase of cells in G0/G1 and G2/M phases of the cell cycle.Western Blot Analysis Cell Line:Caco-2 cells Concentration:32 μM, 64 μM, 128 μM Incubation Time:72 hours Result:Resulted in a down-regulation of cyclin-dependent kinases (cdk) 4 and cdk 6 as well as cyclin D1.
-
体内实验Animal Model:Wild-type 129-SV/eVTAcBr male mice and eNOS-deficient male mice (18-22 g) with the filament model Dosage:2 mg/kg or 20 mg/kg Administration:Delivered via 7- or 14-day ALZET miniosmotic pumps implanted subcutaneously; daily; for 7, 14, or 28 days Result:Increased levels of endothelial nitric oxide synthase (eNOS) mRNA and protein, reduced infarct size, and improved neurological deficits in a dose- and time-dependent manner.
-
同义词Compactin | CS 500 | L-637,312 | ML 236B | NSC 281245 | Statin I
-
通路Metabolic Enzyme/Protease
-
靶点HMGCR
-
受体HMG-CoA reductase| CES1
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number73573-88-3
-
分子量390.51
-
分子式C23H34O5
-
纯度>98% (HPLC)
-
溶解度DMSO: 78mg/ml (199.74 mM);Water: <1mg/ml; Ethanol: <1mg/ml
-
SMILESCC[C@H](C)C(O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@]12[H])=O
-
化学全称(1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Endo A, et al. J Antibiot (Tokyo), 1976, 29(12), 1346-1348.
产品手册




关联产品
-
Rosuvastatin calcium
一种有效的 HMG-CoA 还原酶 (HMGCR) 竞争性抑制剂,IC50 为 11 nM。
-
HMG499
HMG499 是一种有效的选择性 HMG-CoA 还原酶抑制剂,IC50 为 0.41 μM。 HMG499 可以防止他汀类化合物引起的 HMGCR 积累,降低血清胆固醇水平并减少动脉粥样硬化。
-
Rosuvastatin
一种有效的 HMG-CoA 还原酶 (HMGCR) 竞争性抑制剂,IC50 为 11 nM。